Cocrystal Pharma, Inc. (COCP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Cocrystal Pharma, Inc. (COCP) closed at USD 1.04 on 2026-10-14, a change of -9.6 % over the past year, with a market capitalization of USD 19.84M.

Cocrystal Pharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Cocrystal Pharma, Inc. key figures

Previous close

USD 1.04 (2026-10-14)

1-year change

-9.6 %

Market cap

USD 19.84M

Enterprise value

USD 19.01M

P/E ratio (trailing)

-1.34

P/E ratio (forward)

-2.17

EPS (trailing)

-0.77

EPS (forward)

-0.48

PEG ratio

n/a

Price to book

13.55

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.34

Employees

10

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Cocrystal Pharma, Inc. and compare it with other stocks.